Clinically Meaningful Improvement in Atopic Dermatitis According to Treatment Type in a Real-World Cohort
DOI:
https://doi.org/10.2340/actadv.v106.adv-2026-0422Keywords:
atopic dermatitis, minimal clinically important difference, SCORAD, DLQI, biologics, Janus kinase inhibitorsDownloads
References
Schram ME, Spuls PI, Leeflang MMG, Lindeboom R, Bos JD, Schmitt J. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy 2012; 67: 99–106. DOI: https://doi.org/10.1111/j.1398-9995.2011.02719.x
Basra MKA, Salek MS, Camilleri L, Sturkey R, Finlay AY. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology 2015; 230: 27–33. DOI: https://doi.org/10.1159/000365390
Ständer S. Atopic dermatitis. N Engl J Med 2021; 384: 1136–1143. DOI: https://doi.org/10.1056/NEJMra2023911
Fasseeh AN, Elezbawy B, Korra N, Tannira M, Dalle H, Aderian S, et al. Burden of atopic dermatitis in adults and adolescents: a systematic literature review. Dermatol Ther 2022; 12: 2653–2668. DOI: https://doi.org/10.1007/s13555-022-00819-6
Wollenberg A, Christen-Zäch S, Taieb A, Paul C, Thyssen JP, de Bruin-Weller M, et al. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol 2020; 34: 2717–2744. DOI: https://doi.org/10.1111/jdv.16892
Kim RW, Lam M, Abuabara K, Simpson EL, Drucker AM. Targeted systemic therapies for adults with atopic dermatitis: selecting from biologics and JAK inhibitors. Am J Clin Dermatol 2024; 25: 179–193. DOI: https://doi.org/10.1007/s40257-023-00837-w
Siegels D, Heratizadeh A, Abraham S, Binnmyr J, Brockow K, Irvine AD, et al. Systemic treatments in the management of atopic dermatitis: a systematic review and meta-analysis. Allergy 2021; 76: 1053–1076. DOI: https://doi.org/10.1111/all.14631
Rogner D, Biedermann T, Lauffer F. Treatment of atopic dermatitis with baricitinib: first real-life experience. Acta Derm Venereol 2022; 102: adv00677. DOI: https://doi.org/10.2340/actadv.v102.1088
Published
How to Cite
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
